Century Therapeutics appointed Joseph Truitt to its board and granted him an initial option to purchase 148,000 common shares, alongside a $40,000 annual cash retainer. The independent director will join the Compensation Committee as the company advances CNTY-813 toward a 2026 IND submission and CNTY-308 toward clinical entry.

Key Highlights

  • Joseph Truitt will serve on Century Therapeutics’ Compensation Committee through the 2028 Annual Meeting of Stockholders.
  • The new director will receive a $40,000 annual cash retainer under Century Therapeutics’ non-employee director policy.
  • Truitt currently leads iECURE and serves on the boards of Larimar Therapeutics and Code Biotherapeutics.

Century Therapeutics, Inc. (NASDAQ: IPSC) has expanded its board with Joseph Truitt, granting him an initial option to purchase 148,000 common shares. Truitt’s appointment took effect on September 9, 2026, and he will also receive a $40,000 annual cash retainer as a non-employee director.

Truitt Joins Board and Compensation Committee

Truitt will serve as a director until the 2028 Annual Meeting of Stockholders, unless his service ends earlier through resignation, death or removal. Truitt is Chief Executive Officer of iECURE and serves on the boards of Larimar Therapeutics and Code Biotherapeutics. He previously led BioSpecifics Technologies and Achillion Pharmaceuticals, and earlier held commercial and operational roles at Lev Pharmaceuticals, Johnson & Johnson’s OraPharma and TAP Pharmaceuticals. The option award was made under Century Therapeutics’ 2021 Equity Incentive Plan. The company also entered into an indemnification agreement with Truitt in substantially the same form used for its other directors. Both programs are engineered with Century’s Allo-Evasion™ 5.0 platform.